Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer

PURPOSE: Clinical practice guidelines recommend the use of all approved granulocyte colony-stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, as primary febrile neutropenia (FN) prophylaxis in patients receiving high- or intermediate-risk regimens (in those with additional patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Aapro, Matti S., Chaplin, Stephen, Cornes, Paul, Howe, Sebastian, Link, Hartmut, Koptelova, Natalia, Mehl, Andrea, Di Palma, Mario, Schroader, Bridgette Kanz, Terkola, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511548/
https://www.ncbi.nlm.nih.gov/pubmed/37728795
http://dx.doi.org/10.1007/s00520-023-08043-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511548/
https://www.ncbi.nlm.nih.gov/pubmed/37728795
http://dx.doi.org/10.1007/s00520-023-08043-4

Ejemplares similares